CTIS2023-505711-20-00进行中（未招募）1 期
Treatment of non-type 2 CRSwNP with anti-IL-17 antibody (secukinumab) - 1
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 4
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- •CRSwNP diagnosed in accordance to EPOS2020 cirteria, age between 18-64, Previous treatment with glucocorticosteroids and/or surgery have yielded unacceptable disease control, Non-responsive to IL-4/IL-13 antibody (dupilumab) treatment
排除标准
- •Current malignant disease or remission time less than 24 months, Current autoimmune disease or remission time less than 24 months, Using immunosuppressive or biologic treatment less than 8 weeks prior to first study visit, Pregnancy, breastfeeding, Inflammatory bowel disease (Crohn’s disease, ulcerative colitis)., Necessary to administer live vaccines during the treatment period, clinically important, active infection, e.g. active or latent tuberculosis
研究者
相似试验
招募中
2 期
se of Anti-IL-17 in patients with Covid-19 associated pneumoniaCoronavirus infection, unspecifiedCoronavirus infectionsSevere acute respiratory syndrome (SARS)Severe Acute Respiratory SyndromeB34.2C01.925.782.600.550.200C01.748.730RBR-5vpyh4Pesquisador
已完成
2 期
Mechanism of action study of anti-IL17 therapy in spondyloarthritis: impact on cellular and molecular pathways of synovial inflammation and tissue remodelling.ankylosing spondylitisSpondylarthropathy1000381610023213NL-OMON41538Academisch Medisch Centrum20
进行中（未招募）
1 期
Anti-IL-17, a possible new treatment for contact dermatitis?allergic contact dermatitisEUCTR2015-004494-33-DKHerlev and Gentofte Hospital20
进行中（未招募）
不适用
Mechanism of action study of anti-IL17 treatment in spondyloarthritis.MedDRA version: 16.1Level: LLTClassification code 10032155Term: Other inflammatory spondylopathiesSystem Organ Class: 100000004859MedDRA version: 16.1Level: LLTClassification code 10070759Term: SpondylopathySystem Organ Class: 100000004859SpondyloarthritisEUCTR2013-002709-79-NLAcademic Medical Center, Department of Rheumatology
招募中
1 期
Phase I/II study of anti-CD7 Chimeric Antigen Receptor-Expressing T cells in pediatric patients/young adult affected by relapsed/refractory CD7+ T-cell Acute Lymphoblastic Leukemia/LymphomaRelapsed/refractory CD7+ T-cell Acute Lymphoblastic Leukemia/LymphomaMedDRA version: 21.1Level: LLTClassification code: 10066110Term: T-cell lymphoblastic leukemia acute Class: 10029104MedDRA version: 20.0Level: PTClassification code: 10042971Term: T-cell lymphoma Class: 100000004864CTIS2023-508355-39-00Ospedale Pediatrico Bambino Gesu'26